Zymeworks price target raised to $14 from $12 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on Zymeworks (ZYME) to $14 from $12 and keeps an Overweight rating on the shares. The firm notes ZW49’s de-prioritizartion makes Zymeworks a pre-clinical story now, though Jazz Pharmaceuticals’ (JAZZ) March 19th R&D day, which will exclusively focus on zani opptys probably offers some upside for shares.